Description
Description
The incidence of and the death rate from cardiovascular and cerebrovascular diseases are increasing in China with the development of economy, the change of lifestyle and the aging of the population. It is estimated that nearly 300 million people in China are suffering from cardiovascular and cerebrovascular diseases. The number of patients with stroke, coronary heart disease, heart failure, pulmonary heart disease, rheumatic heart disease, congenital heart disease and hypertension amounts to 13 million, 11 million, 4.5 million, 5 million, 2.5 million, 2 million and 270 million respectively. With a higher death rate than tumors and other diseases, cardiovascular diseases account for more than 40% disease deaths in China. In particular, rural areas have seen higher death rate from cardiovascular diseases than urban areas in recent years. And the costs of hospitalization resulting from cardiovascular and cerebrovascular diseases are also increasing sharply.
Pancreatic Kininogenase can be used to treat cardiovascular and cerebrovascular diseases such as primary hypertension, arteriosclerosis, coronary atherosclerotic heart disease, cerebral arteriosclerosis, cerebral thrombosis, retinal vascular disorder and peripheral vascular disease. Recent studies have found that Pancreatic Kininogenase can also be used to prevent diabetic microangiopathy and early diabetic nephropathy by reducing the discharge of urinary albumin. In addition, Pancreatic Kininogenase can increase the activity and production of sperms, and thus has certain curative effect on male infertility, according to domestic clinical data.
In 1999, Changzhou Qianhong Bio-pharma Co., Ltd.’s Pancreatic Kininogenase was first launched in China, followed by the counterparts of Chengdu Tongde Pharmaceutical Co., Ltd., Henan Livu Pharmacy Co., Ltd., Shanghai Livzon Pharmaceutical Co., Ltd., etc. At present, there are seven Pancreatic Kininogenase manufacturers in China. Changzhou Qianhong Bio-pharma Co., Ltd.’s Pancreatic Kininogenase (trade name: Yikai) takes up about 90% market share by sales value.
It is expected that as the incidence of cardiovascular and cerebrovascular diseases continues to increase, China’s Pancreatic Kininogenase market will still have some growth potential in the next few years.
Topics Covered:
– Situation of cardiovascular and cerebrovascular diseases in China
– Status of China’s Pancreatic Kininogenase market
– Competition on China’s Pancreatic Kininogenase market
– Factors influencing the development of China’s Pancreatic Kininogenase market
– Prospect of China’s Pancreatic Kininogenase market
Table of Contents
Table of Contents
1 Relevant Concepts of Pancreatic Kininogenase
1.1 Indications for Pancreatic Kininogenase
1.2 Development of Pancreatic Kininogenase in China
1.3 Government Approval of Pancreatic Kininogenase in China
2 Sales of Pancreatic Kininogenase in China, 2013-2017
2.1 Sales Value of Pancreatic Kininogenase
2.1.1 Overall Sales Value
2.1.2 Sales Value by Region
2.2 Sales Volume of Pancreatic Kininogenase
2.2.1 Overall Sales Volume
2.2.2 Sales Volume by Region
2.3 Sales of Pancreatic Kininogenase by Dosage Form in China, 2013-2017
2.3.1 Pancreatic Kininogenase Injections
2.3.2 Pancreatic Kininogenase Tablets
3 Analysis on Major Pancreatic Kininogenase Manufacturers in China, 2013-2017
3.1 Analysis on Market Share of Major Pancreatic Kininogenase Manufacturers in China
3.1.1 Market Share by Sales Value
3.1.2 Market Share by Sales Volume
3.2 Shanghai Livzon Pharmaceutical Co., Ltd.
3.2.1 Enterprise Profile
3.2.2 Sales of Shanghai Livzon Pharmaceutical Co., Ltd.’s Pancreatic Kininogenase in China
3.3 Sichuan Shunsheng Pharmaceutical Co., Ltd.
3.3.1 Enterprise Profile
3.3.2 Sales of Sichuan Shunsheng Pharmaceutical Co., Ltd.’s Pancreatic Kininogenase in China
3.4 Changzhou Qianhong Bio-pharma Co., Ltd.
3.5 Chengdu Tongde Pharmaceutical Co., Ltd.
3.6 Henan Livu Pharmacy Co., Ltd.
4 Prices of Pancreatic Kininogenase in China, 2017-2018
4.1 Shanghai Livzon Pharmaceutical Co., Ltd. (Guangle)
4.2 Sichuan Shunsheng Pharmaceutical Co., Ltd. (Dashun)
4.3 Changzhou Qianhong Bio-pharma Co., Ltd. (Yikai)
4.4 Chengdu Tongde Pharmaceutical Co., Ltd. (Tongde)
4.5 Henan Livu Pharmaceutical Co., Ltd. (Duomeile)
5 Prospect of China’s Pancreatic Kininogenase Market, 2018-2022
5.1 Factors Influencing Development Pancreatic Kininogenase Market
5.2 Forecast on Market Size
5.3 Forecast on Market Trend
Selected Charts
Chart Government Approval of Pancreatic Kininogenase in China
Chart Sales Value of Pancreatic Kininogenase in China, 2013-2017
Chart Sales Value of Pancreatic Kininogenase in Parts of China, 2013-2017
Chart Sales Volume of Pancreatic Kininogenase in China, 2013-2017
Chart Sales Volume of Pancreatic Kininogenase in Parts of China, 2013-2017
Chart Sales Value of Pancreatic Kininogenase Injections in China, 2013-2017
Chart Sales Volume of Pancreatic Kininogenase Injections in China, 2013-2017
Chart Sales Value of Pancreatic Kininogenase Tablets in China, 2013-2017
Chart Market Share of Top 5 Pancreatic Kininogenase Manufacturers by Sales Value in China, 2013-2017
Chart Market Share of Top 5 Pancreatic Kininogenase Manufacturers by Sales Volume in China, 2013-2017
Chart Sales Value of Shanghai Livzon Pharmaceutical Co., Ltd.’s Pancreatic Kininogenase, 2013-2017
Chart Sales Volume of Shanghai Livzon Pharmaceutical Co., Ltd.’s Pancreatic Kininogenase, 2013-2017
Chart Sales Value of Sichuan Shunsheng Pharmaceutical Co., Ltd.’s Pancreatic Kininogenase, 2013-2017
Chart Sales Value of Changzhou Qianhong Bio-pharma Co., Ltd.’s Pancreatic Kininogenase, 2013-2017
Chart Sales Value of Chengdu Tongde Pharmaceutical Co., Ltd.’s Pancreatic Kininogenase, 2013-2017
Chart Prices of Shanghai Livzon Pharmaceutical Co., Ltd.’s Pancreatic Kininogenase in Parts of China, 2017-2018
Chart Prices of Sichuan Shunsheng Pharmaceutical Co., Ltd.’s Pancreatic Kininogenase in Parts of China, 2017-2018
Chart Prices of Changzhou Qianhong Bio-pharma Co., Ltd.’s Pancreatic Kininogenase in Parts of China, 2017-2018
Chart Forecast on Sales Value of Pancreatic Kininogenase in China, 2018-2022
